Functional and biocompatible polymeric nanopatricels for targetted PET imaging of neuroendocrine tumors.

Polymeric nanoparticles are currently being exploited because of their ability to incorporate multifunctionality and ease of synthesis in different volumes, architectures and physical/chemical properties. They can be adorned with molecules and polymeric chains which not only sterically protect th...

全面介紹

Saved in:
書目詳細資料
主要作者: Singh Medha.
其他作者: Liu Quan
格式: Theses and Dissertations
語言:English
出版: 2013
主題:
在線閱讀:http://hdl.handle.net/10356/54338
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!
機構: Nanyang Technological University
語言: English
實物特徵
總結:Polymeric nanoparticles are currently being exploited because of their ability to incorporate multifunctionality and ease of synthesis in different volumes, architectures and physical/chemical properties. They can be adorned with molecules and polymeric chains which not only sterically protect them from opsonization, but also equip them with active targeting, improving overall specificity for diagnostic imaging. We have utilized reversible addition-fragmentation chain-transfer (RAFT) polymerization for the synthesis of the biocompatible and functional polymeric nanoparticles for positron-emission tomography (PET) imaging of neuroendocrine tumor cells. The novel monomer, 4-methyl methacrylate [2- (2-hydroxyethoxy)ethoxy]benzoic acid was copolymerized with oligo(ethylene glycol) methyl ether methacrylate to render it hydrophilic with polydispersity index (PDI) in the range of (1.23-1.60). The polymer was then successfully functionalized for incorporating N-Hydroxy succinimide(NHS) activated ester for peptide conjugation. The nanoparticles obtained after incorporating DOTA chelator for radionuclide encapsulation had low polydispersity index (0.128-0.326) and hydrodynamic diameter (by intensity) in the range of 20 nm- 35 nm. These novel DOTA-functional polymeric nanoparticles aimed at improving targeted visualization of tumor cells after successful peptide conjugation have potential to improve cancer management, drug dosage and radiotherapy regimes of the patients.